Modifications in Acute Phase and Complement Systems Predict Shifts in Cognitive Status of HIV-infected Patients

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2017 Jun 3

PMID 28574961

Citations 4

Authors

Ceereena Ubaida-Mohien

Benjamin Lamberty

Alex M Dickens

Michelle M Mielke

Thomas Marcotte

Ned Sacktor

Igor Grant

Scott Letendre

Donald Franklin

Pawel Cibrowski

Ravi Tharakan

Justin C McArthur

Howard Fox

Norman J Haughey

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of HIV-associated neurocognitive disorders (HAND) has not changed considerably in the last two decades. Potent antiretroviral therapy has shifted the severity of HAND to milder phenotypes, but excess morbidity and mortality continue to be associated with HAND. Changes in numerous markers of immune function, inflammation, and cellular stress have been repeatedly associated with HAND, but the underlying systems that drive these changes have not been identified.

Method: In this study, we used systems informatics to interrogate the cerebrospinal fluid proteomic content of longitudinal samples obtained from HIV-infected adults with stably unimpaired, stably impaired, worsening, or improving neurocognitive performance.

Results And Conclusion: The patterns of change in cerebrospinal fluid protein content implicated the induction of acute phase and complement systems as important regulators of neurocognitive status. Worsening neurocognitive performance was preceded by induction of acute phase and complement systems, whereas improving neurocognitive performance was preceded by a downregulation of these systems.

Citing Articles

Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options.

Luz I, Takaya R, Ribeiro D, Castro M, Fontes W Adv Exp Med Biol. 2024; 1443:221-242.

PMID: 38409424 DOI: 10.1007/978-3-031-50624-6_12.

Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses.

Sperk M, van Domselaar R, Rodriguez J, Mikaeloff F, Vinhas B, Saccon E J Proteome Res. 2020; 19(11):4259-4274.

PMID: 33095583 PMC: 7640957. DOI: 10.1021/acs.jproteome.0c00380.

Proteomic analysis of cerebrospinal fluid extracellular vesicles reveals synaptic injury, inflammation, and stress response markers in HIV patients with cognitive impairment.

Guha D, Lorenz D, Misra V, Chettimada S, Morgello S, Gabuzda D J Neuroinflammation. 2019; 16(1):254.

PMID: 31805958 PMC: 6896665. DOI: 10.1186/s12974-019-1617-y.

Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder.

Wu M, Zhang X, Asher M, Thayer S Brain Res. 2019; 1724:146467.

PMID: 31539547 PMC: 6880862. DOI: 10.1016/j.brainres.2019.146467.

References

Kore I, Ananworanich J, Valcour V, Fletcher J, Chalermchai T, Paul R . Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015; 70(4):393-9. PMC: 4625393. DOI: 10.1097/QAI.0000000000000746. View

Grant I, Franklin Jr D, Deutsch R, Woods S, Vaida F, Ellis R . Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014; 82(23):2055-62. PMC: 4118496. DOI: 10.1212/WNL.0000000000000492. View

Zhang K, Kaufman R . From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008; 454(7203):455-62. PMC: 2727659. DOI: 10.1038/nature07203. View

Mohamed M, Barker P, Skolasky R, Selnes O, Moxley R, Pomper M . Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging. 2010; 28(9):1251-7. PMC: 2963667. DOI: 10.1016/j.mri.2010.06.007. View

Towgood K, Pitkanen M, Kulasegaram R, Fradera A, Soni S, Sibtain N . Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. Hum Brain Mapp. 2012; 34(10):2484-93. PMC: 6869962. DOI: 10.1002/hbm.22078. View

Calcagno A, Alberione M, Romito A, Imperiale D, Ghisetti V, Audagnotto S . Prevalence and predictors of blood-brain barrier damage in the HAART era. J Neurovirol. 2014; 20(5):521-5. DOI: 10.1007/s13365-014-0266-2. View

Stauch K, Purnell P, Fox H . Aging synaptic mitochondria exhibit dynamic proteomic changes while maintaining bioenergetic function. Aging (Albany NY). 2014; 6(4):320-34. PMC: 4032798. DOI: 10.18632/aging.100657. View

Canestri A, Lescure F, Jaureguiberry S, Moulignier A, Amiel C, Marcelin A . Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010; 50(5):773-8. DOI: 10.1086/650538. View

McArthur J, Hoover D, Bacellar H, Miller E, Cohen B, Becker J . Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993; 43(11):2245-52. DOI: 10.1212/wnl.43.11.2245. View

10.

Marcotte T, Deutsch R, Michael B, Franklin D, Cookson D, Bharti A . A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013; 8(5):1123-35. PMC: 3874146. DOI: 10.1007/s11481-013-9504-2. View

11.

Cysique L, Franklin Jr D, Abramson I, Ellis R, Letendre S, Collier A . Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011; 33(5):505-22. PMC: 3151558. DOI: 10.1080/13803395.2010.535504. View

12.

Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D . Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012; 206(2):275-82. PMC: 3490695. DOI: 10.1093/infdis/jis326. View

13.

Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman H, Wojna V, Melendez L . Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res. 2007; 6(11):4189-99. DOI: 10.1021/pr070220c. View

14.

Ferrington D, Gregerson D . Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci. 2012; 109:75-112. PMC: 4405001. DOI: 10.1016/B978-0-12-397863-9.00003-1. View

15.

Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D . Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis. 2013; 13:203. PMC: 3655873. DOI: 10.1186/1471-2334-13-203. View

16.

Reboul J, Schuller E, Pialoux G, Rey M, Lebon P, Allinquant B . Immunoglobulins and complement components in 37 patients infected by HIV-1 virus: comparison of general (systemic) and intrathecal immunity. J Neurol Sci. 1989; 89(2-3):243-52. DOI: 10.1016/0022-510x(89)90026-9. View

17.

Jahoor F, Jackson A, Gazzard B, Philips G, Sharpstone D, Frazer M . Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Am J Physiol. 1999; 276(1):E205-11. DOI: 10.1152/ajpendo.1999.276.1.E205. View

18.

Ernst T, Jiang C, Nakama H, Buchthal S, Chang L . Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging. 2010; 32(5):1045-53. PMC: 2967445. DOI: 10.1002/jmri.22366. View

19.

Fois A, Brew B . The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication. Curr HIV/AIDS Rep. 2015; 12(2):299-303. DOI: 10.1007/s11904-015-0257-9. View

20.

Lindl K, Akay C, Wang Y, White M, Jordan-Sciutto K . Expression of the endoplasmic reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. Neuropathol Appl Neurobiol. 2007; 33(6):658-69. DOI: 10.1111/j.1365-2990.2007.00866.x. View